NCT04535856View on ClinicalTrials.gov

Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 14, 2020

Primary Completion Date

January 14, 2021

Study Completion Date

January 14, 2021

Conditions
Covid19Corona Virus InfectionSAR
Interventions
DRUG

allogeneic mesenchymal stem cell

"Assignment of Administration Group allogeneic mesenchymal stem cell:~* Low-dose group (5 x 10\^7cells)~* High-dose group (1 x 10\^8 cells)"

OTHER

Placebo

Control group (placebo)

Trial Locations (1)

90245

Site 550: University of Hassanudin/ Dr. Wahidin Sudirohusodo Hospital, Makassar

Sponsors
All Listed Sponsors
collaborator

National Institute of Health Research and Development, Ministry of Health Republic of Indonesia

OTHER

collaborator

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

lead

Ina-Respond

OTHER

NCT04535856 - Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients | Biotech Hunter | Biotech Hunter